The development of blood-based AD biomarkers (detecting analytes such as those involved in protein misfolding [e.g., amyloid-β, phosphorylated tau] or neuroinflammation) may emerge as potentially accessible, non-invasive and inexpensive screening tools [22,49]. This evidence concerns the gene MAPT and Alzheimer disease.